These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 9102219

  • 1. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice.
    Sun LQ, Vogel CA, Mirimanoff RO, Coucke P, Slosman DO, Mach JP, Buchegger F.
    Cancer Res; 1997 Apr 01; 57(7):1312-9. PubMed ID: 9102219
    [Abstract] [Full Text] [Related]

  • 2. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice.
    Buchegger F, Rojas A, Delaloye AB, Vogel CA, Mirimanoff RO, Coucke P, Sun LQ, Raimondi S, Denekamp J, Pèlgrin A.
    Cancer Res; 1995 Jan 01; 55(1):83-9. PubMed ID: 7805046
    [Abstract] [Full Text] [Related]

  • 3. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice.
    Vogel CA, Galmiche MC, Buchegger F.
    Cancer Res; 1997 Feb 01; 57(3):447-53. PubMed ID: 9012472
    [Abstract] [Full Text] [Related]

  • 4. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [Abstract] [Full Text] [Related]

  • 5. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations.
    Chalandon Y, Mach JP, Pèlegrin A, Folli S, Buchegger F.
    Anticancer Res; 1992 Dec 01; 12(4):1131-9. PubMed ID: 1503403
    [Abstract] [Full Text] [Related]

  • 6. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 7. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 8. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.
    J Nucl Med; 2006 Jul 01; 47(7):1127-35. PubMed ID: 16818947
    [Abstract] [Full Text] [Related]

  • 9. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.
    Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, Begent RH.
    Cancer Res; 1996 Jul 15; 56(14):3293-300. PubMed ID: 8764124
    [Abstract] [Full Text] [Related]

  • 10. Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model.
    Roberson PL, Buchsbaum DJ.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5811s-5816s. PubMed ID: 7493351
    [Abstract] [Full Text] [Related]

  • 11. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells.
    Li XF, Kinuya S, Yokoyama K, Koshida K, Mori H, Shiba K, Watanabe N, Shuke N, Michigishi T, Tonami N.
    Eur J Nucl Med Mol Imaging; 2002 Dec 01; 29(12):1669-74. PubMed ID: 12458402
    [Abstract] [Full Text] [Related]

  • 12. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study.
    Buchegger F, Allal AS, Roth A, Papazyan JP, Dupertuis Y, Mirimanoff RO, Gillet M, Pelegrin A, Mach JP, Slosman DO.
    Anticancer Res; 2000 Dec 01; 20(3B):1889-96. PubMed ID: 10928122
    [Abstract] [Full Text] [Related]

  • 13. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, Lorf T, Post S, Wörmann B, Hiddemann W, Ringe B, Becker W.
    Anticancer Res; 1999 Dec 01; 19(4A):2427-32. PubMed ID: 10470170
    [Abstract] [Full Text] [Related]

  • 14. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [Abstract] [Full Text] [Related]

  • 15. Radioimmunotherapy of carcinoma of colon with [131I]-labeled recombinant chimeric monoclonal antibodies to carcinoembryonic antigen.
    Lu QJ, Bian GX, Chen YY, Zhang M, Guo SM, Wen LQ.
    Acta Pharmacol Sin; 2005 Oct 01; 26(10):1259-64. PubMed ID: 16174444
    [Abstract] [Full Text] [Related]

  • 16. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
    Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Booth BJ, Pavlinkova G, Tempero M, Batra SK.
    Clin Cancer Res; 2001 Jan 01; 7(1):175-84. PubMed ID: 11205906
    [Abstract] [Full Text] [Related]

  • 17. 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft.
    Barendswaard EC, O'Donoghue JA, Larson SM, Tschmelitsch J, Welt S, Finn RD, Humm JL.
    J Nucl Med; 1999 Oct 01; 40(10):1764-8. PubMed ID: 10520720
    [Abstract] [Full Text] [Related]

  • 18. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, Martin M, Le Doussal JM, Barbet J.
    J Nucl Med; 2000 Mar 01; 41(3):480-7. PubMed ID: 10716323
    [Abstract] [Full Text] [Related]

  • 19. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
    Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH.
    Cancer Res; 2001 Jun 15; 61(12):4716-22. PubMed ID: 11406542
    [Abstract] [Full Text] [Related]

  • 20. Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts.
    Sautter-Bihl ML, Wessely R, Bihl H.
    Strahlenther Onkol; 1993 Oct 15; 169(10):595-600. PubMed ID: 8235984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.